Research outlook of new drugs in 2012

After experiencing a continuous reduction of staff and closing some R & D institutions, the world's major pharmaceutical companies begin to strengthen internal integration efforts and return to their expertise areas .Some has best wishes on the new R & D model as well as new therapeutic areas.

Drug discovery continues from an increasingly competitive field of hepatitis C drugs are frequent, to the era of individualized cancer treatment; more and more attention from the long-term available diabetes drugs development, to a rare disease drugs; popular areas of the fierce competition of the hyperlipidemia drug to the launch of a new respiratory drug, each of these areas do not lack the assiduous pursuer.

New cholesterol-lowering drug - the cholesterol ester transfer protein inhibitors, may will have to wait for several years. CETP inhibition can indeed reduce the occurrence of atherosclerosis of, but it will also lead to the occurrence of cardiovascular events, but analysts firmly believe that these pharmaceutical raw materials drugs which would be achieved blockbuster level status. Although the first CETP inhibition - in 2006 the torcetrapib experienced mortality, but some people think, the torcetrapib test of hypertension-related diseases caused by the hormone death is just an isolated incident of the CETP inhibitor.

Hospitalization led to the super bacteria infections including hospital-acquired pneumonia, skin infections, urinary tract infection are expected that the drug market from 2010 to $ 3,300,000,000 to $ 4,000,000,000 in 2020. Treatment of super bacteria drug Cubicin is expected before June 2017 will not be the challenge of generic drugs, Cubicin of income also contribute to the company late stage candidates (e.g., CXA-201) development. CXA-201 has entered phase III clinical test.

Although some people think that the U.S. Food and Drug Administration for approval of drugs for diabetes and other metabolic syndrome is too cautious, but the development of these drugs continues, after all, the diabetes drug market is the world's fourth largest drug market. According to the report of the U.S. pharmaceutical market consulting research firm IMS, the drug market in 2010 reached $ 34.4 billion, an increase of 12 percent more than in 2009.

BG-12 is an oral multiple sclerosis drug, is expected this year. Large-scale clinical trials compared with placebo, the proportion of BG-12 (240 mg, 2 or 3 times a daily) after taking two years, will enable multiple sclerosis relapse in patients with reduced by 49% and 50% . Other oral drugs such as Gilenya, the problem is, efficacy relative to side effects there is no absolute compelling advantages. The Gilenya side effects may be exaggerated, these side effects and dosage and gradually increase in. BG-12 has a good effect, will share the Gilenya of the market share and can be used in patients with early multiple sclerosis.

Currently known rare diseases, there are about 7000 kinds, there are a number of biopharmaceutical companies (especially those with specific R & D infrastructure), is the rare disease drug development. Among them, the largest of the three types of rare disease resveratrol drugs field is enzyme replacement therapy, pulmonary artery hypertension and of hereditary angioedema.

Patients of alzheimer disease are about 26 million. In the field of alzheimer drug, there are no alleviate disease drugs listed. Late-stage clinical trials of these drugs will experience a long-term, regulators stringent review process. Currently, bapineuzumab is in III clinical stage. In addition, developing drug solanezumab is targeting on amyloid. It is expected that the two involve in 1000 patients. 8-month trial (mild to moderate alzheimer disease) will be completed in the first half of this year. However, alzheimer disease likes parkinson disease. It is a hard nut to treat. But pharmaceutical companies see a market with a promising future.Source:http://www.cospcn.com